Does Shire Have The Strategy To Deliver On Rare Opportunity In Early/Mid Pipeline?
Executive Summary
The biotech laid out its pipeline during a Dec. 10 R&D day in hopes of convincing analysts and investors that its rare disease focus will pay off in coming years.